30 Jun 2011 07:00
Embargoed: 0700hrs 30 June 2011
Akers Biosciences, Inc.
("ABI" or the "Company")
US$3.2 Million Purchase Order - Revelar Free Radical Assay
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, has secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar breath tubes to Pulse Health, LLC under the Company's Supply Agreement, as announced on 11 April 2011. This is the first purchase order under the Supply Agreement and manufacturing will commence immediately, from ABI's New Jersey facility, with the majority of this order expected to be fulfilled during 2011.
Revelar provides the first accurate measurement system that both detects and measures aldehydes in exhaled breath. Aldehydes are known to be indicators of free radical activity that are thought to negatively impact or damage healthy cells throughout the human body. External factors, such as diet, activity, stress, chemicals and pollutants cause the body to produce excess free radicals that damage healthy cells. Studies show this may lead to heart disease, cancer and rapid aging.
Millions of people in the developed world are consuming antioxidant supplements to counteract this process but neither patients, nor healthcare practitioners, have previously been able to accurately and efficiently determine whether a regime is working to improve patient health. The Revelar Assay, which consists of an electronic analyser and disposable breath tubes, instantly measures a patient's baseline aldehyde level and provides a numerical score, providing the first rapid, non-invasive way to measure the effectiveness of an antioxidant regimen and other interventions.
Pulse Health, LLC, based in Portland, Oregon, is supplying The Revelar Assay to healthcare practitioners - particularly chiropractic centres - and health supplement producers and distributors initially in the USA and throughout the EU and then worldwide, where the sale of antioxidant products represents a multi-billion dollar annual market.
Thomas A. Nicolette, President and Chief Executive of ABI, commented,
"Pulse Health has identified a significant opportunity to provide an easy-to-use assay that empowers patients and healthcare practitioners with the knowledge to evaluate the effectiveness of a regime and adapt accordingly. We are extremely excited to be supplying this truly progressive test using ABI's proprietary breath condensate collection technology."
Enquiries:
Thomas A. Nicolette, President and CEO
Tel. +1 856 848 8698
Antony Legge or Noelle Greenaway
Daniel Stewart & Company plc (Nomad and Broker)
Tel. +44 (0)20 7776 6550
Ben Simons
M: Communications
Tel. +44 (0)20 7920 2340
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com